SLC1A5 and neoplasm: Since tumor cells and effector T cells exhibit different abilities to upregulate SLC1A5 in a tryptophan‐depleted environment, tumor cells gain a competitive advantage in capturing Trp, helping to deplete Trp in the tumor microenvironment (TME) and suppressing effector T‐cell activation, thus inhibiting their immune function [58].